Answers are grounded in this paper and cite their sources.
Islet amyloid polypeptide (IAPP) is a β-cell peptide hormone, cosecreted with insulin, that critically regulates postprandial glucose metabolism. Under β-cell stress, IAPP self-assembles into toxic amyloid fibrils, resulting in dysfunction, cytotoxicity, and loss of β-cell mass, which typically occurs in the onset of type 2 diabetes. Polyphenols are dietary bioactives with antifibrillation activities across the IAPP aggregation cascade by intercepting nucleation, arresting elongation, stabilizing off-pathway oligomers, and remodelling preformed amyloid fibrils. Polyphenols also modulate downstream toxicity axes including membrane disruption, endoplasmic reticulum stress, and unfolded protein response, thus alleviating mTORC1-driven autophagy/mitophagy impairment and oxidative stress via Nrf2/ARE upregulation. This review evaluates the mechanistic and translational evidence for polyphenols as IAPP-modulating cytoprotective food bioactives. Furthermore, challenges with bioavailability and biostability, the disaggregation paradox, the pharmacokinetic gap between assay and plasma concentration, and species-specific limitations in vivo are discussed as major translational barriers requiring future investigations.
No takes yet. Share an insight, caveat, or question.
Hum et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: